Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay

Oncogene volume 28, pages 610–618 (2009)Cite this article

Abstract

The pupose of this study was to evaluate the activity of ON 01910.Na, a mitotic inhibitor, in in vitro and in vivo models of pancreatic cancer and to discover biomarkers predictive of efficacy. Successive in vitro and in vivo models were used; these included cell line-derived and patient-derived tumors from our PancXenoBank, a live collection of freshly generated pancreatic cancer xenografts. ON 01910.Na showed equivalent activity to gemcitabine against pancreatic cancer cell lines in vitro. The activity of the agent correlated with suppression of phospho-CDC25C and cyclin B1. These markers were optimized for a fine-needle aspirate ex vivo rapid assay. Cyclin B1 mRNA evaluation yielded the most optimal combination of accuracy and reproducibility. Next, nine patient-derived tumors from the PancXenoBank were profiled using the assay developed in cell lines and treated with ON01910.Na for 28 days. Two cases were cataloged as potential responders and seven as resistants. There was a correlation between the ex vivo assay and sensitivity to the tested agent, as the two cases prospectively identified as sensitive met prespecified criteria for response. Of the seven tumors of predictive resistant, only one was found to be sensitive to ON 01910.Na. In addition, there was a good correlation between cyclin B1 downregulation ex vivo and changes in cyclin B1 protein post-treatment. The novel mitotic inhibitor, ON 01910.Na, showed activity in preclinical model of pancreatic cancer. A rapid assay was rationally developed that not only identified cases sensitive to ON 01910.Na, but also anticipated the pharmacodynamic events occurring after in vivo exposure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Budirahardja Y, Gonczy P . (2008). PLK-1 asymmetry contributes to asynchronous cell division of C. elegans embryos. Development 135: 1303–1313.

    Article  CAS  Google Scholar 

  • Dvory-Sobol H, Cohen-Noyman E, Kazanov D, Figer A, Birkenfeld S, Madar-Shapiro L et al. (2006). Celecoxib leads to G2/M arrest by induction of p21 and downregulation of cyclin B1 expression in a p53-independent manner. Eur J Cancer 42: 422–426.

    Article  CAS  Google Scholar 

  • Gonczy P . (2008). Mechanisms of asymmetric cell division: flies and worms pave the way. Nat Rev Mol Cell Biol 9: 355–366.

    Article  Google Scholar 

  • Gumireddy K, Reddy MV, Cosenza SC, Boominathan R, Baker SJ, Papathi N et al. (2005). ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7: 275–286.

    Article  CAS  Google Scholar 

  • Hassan KA, Ang KK, El-Naggar AK, Story MD, Lee JI, Liu D et al. (2002). Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 62: 6414–6417.

    CAS  PubMed  Google Scholar 

  • Hidalgo M, Amador ML, Jimeno A, Mezzadra H, Patel P, Chan A et al. (2006). Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. Mol Cancer Ther 5: 1895–1903.

    Article  CAS  Google Scholar 

  • Jackman M, Lindon C, Nigg EA, Pines J . (2003). Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol 5: 143–148.

    Article  CAS  Google Scholar 

  • Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ . (2007). Cancer statistics, 2007. CA Cancer J Clin 57: 43–66.

    Article  Google Scholar 

  • Jimeno A, Kulesza P, Kincaid E, Bouaroud N, Chan A, Forastiere A et al. (2006). C-fos assessment as a marker of anti-epidermal growth factor receptor effect. Cancer Res 66: 2385–2390.

    Article  CAS  Google Scholar 

  • Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M et al. (2008). Phase I Study of ON 01910.Na, a novel modulator of the polo-like kinase 1 pathway, in adult patients with solid tumours. J Clin Oncol (e-pub ahead of print, 27 October 2008).

  • Jimeno A, Rubio-Viqueira B, Amador ML, Oppenheimer D, Bouraoud N, Kulesza P et al. (2005). Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 65: 3003–3010.

    Article  CAS  Google Scholar 

  • Jimeno A, Tan A, Garrido-Laguna I, Solomo A, Hruban R, Schulick R et al. A prospective clinical validation of a direct xenograft pancreatic cancer approach. 2008 ASCO Annual Meeting, oral presentation. (abstract 4500).

  • Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801–1806.

    Article  CAS  Google Scholar 

  • Korenaga D, Takesue F, Yasuda M, Honda M, Nozoe T, Inutsuka S . (2002). The relationship between cyclin B1 overexpression and lymph node metastasis in human colorectal cancer. Surgery 131: S114–S120.

    Article  Google Scholar 

  • Li J, Zhao M, Jimeno A, He P, Ramana Reddy MV, Hidalgo M et al. (2007). Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 856: 198–204.

    Article  CAS  Google Scholar 

  • Nigg EA . (1998). Polo-like kinases: positive regulators of cell division from start to finish. Curr Opin Cell Biol 10: 776–783.

    Article  CAS  Google Scholar 

  • Park M, Chae HD, Yun J, Jung M, Kim YS, Kim SH et al. (2000). Constitutive activation of cyclin B1-associated cdc2 kinase overrides p53-mediated G2-M arrest. Cancer Res 60: 542–545.

    CAS  PubMed  Google Scholar 

  • Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C et al. (2006). An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 12: 4652–4661.

    Article  CAS  Google Scholar 

  • Samson DJ, Seidenfeld J, Ziegler K, Aronson N . (2004). Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol 22: 3618–3630.

    Article  CAS  Google Scholar 

  • Schmidt M, Hofmann HP, Sanders K, Sczakiel G, Beckers TL, Gekeler V . (2006). Molecular alterations after Polo-like kinase 1 mRNA suppression versus pharmacologic inhibition in cancer cells. Mol Cancer Ther 5: 809–817.

    Article  CAS  Google Scholar 

  • Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR . (2004). American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22: 3631–3638.

    Article  CAS  Google Scholar 

  • Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783–792.

    Article  CAS  Google Scholar 

  • Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH . (2000). Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2: 672–676.

    Article  CAS  Google Scholar 

  • Yuan J, Kramer A, Matthess Y, Yan R, Spankuch B, Gatje R et al. (2006). Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene 25: 1753–1762.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was supported in part by the Viragh Foundation and Onconova Inc.

Author information

Authors and Affiliations

  1. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA

    A Jimeno, A Chan, G Cusatis, X Zhang, J Wheelhouse, A Solomon, F Chan, M Zhao, M A Rudek, R C Donehower & M Hidalgo

  2. Department of Biochemistry, Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, USA

    S C Cosenza, MV Ramana Reddy & E P Reddy

  3. Department of Pathology, Wallace Tumor Institute, University of Alabama at Birmingham, Birmingham, AL, USA

    P Kulesza

Authors
  1. A Jimeno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Cusatis
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. X Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Wheelhouse
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Solomon
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Chan
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S C Cosenza
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. MV Ramana Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M A Rudek
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. P Kulesza
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R C Donehower
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. E P Reddy
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. M Hidalgo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Hidalgo.

Additional information

Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jimeno, A., Chan, A., Cusatis, G. et al. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene 28, 610–618 (2009). https://doi.org/10.1038/onc.2008.424

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2008.424

Keywords

This article is cited by

Search

Advanced search

Quick links